SLC25A3P2

Across TCGA pan-cancer cohorts, SLC25A3P2 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of SLC25A3P2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where SLC25A3P2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC25A3P2 is over-expressed in tumor, although a few such as KIRC and STAD show the opposite, repressed pattern.

COAD, KICH, and KIRC are the cancer types where SLC25A3P2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC25A3P2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	All	All	+0.278	.002	5	view →
KICH	All	All	+0.081	.001	5	view →
KIRC	Female	III,IV	−0.058	.014	3	view →
HNSC	Female	IV	+0.055	.010	3	view →
STAD	All	III,IV	−0.275	.024	2	view →
THCA	Male	III,IV	+0.114	.010	2	view →
LIHC	Male	All	+0.023	.010	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

SLC25A3P2–COAD

Open the COAD breakdown →